Involvement of VKORC1 in the inhibition of calcium oxalate crystal formation in HK-2 cells

Abstract

The vitamin K epoxide reductase complex subunit 1 (VKORC1), the rate-limiting enzyme for vitamin K recycling, is significantly down-regulated in the kidneys of urolithiasis patients. This study searched for direct evidence to define the inhibitory activity of VKORC1 against calcium oxalate (CaOx) crystal formation. In the experiment of VKORC1 overexpression, HK-2 cells were transfected with the pFLAG-CMV-7.1-VKORC1 plasmid as a pFLAG-CMV-7.1-VKORC1 transfection group or the pFLAG-CMV-7.1 plasmid as a pFLAG-CMV-7.1 control group. In the experiment of VKORC1 knockdown, HK-2 cells were transfected with the PGPU6/GFP/Neo-VKORC1shRNA-2 as a PGPU6/GFP/Neo-VKORC1shRNA-2 transfection group or the PGPU6/GFP/Neo-shRNA-NC plasmid as a PGPU6/GFP/Neo-shRNA-NC control group. The expression of VKORC1 in HK-2 cells was detected by real-time quantitative PCR and Western blotting. The CaOx crystal formation was observed under the laser-scanning confocal microscope. It was found that the expression levels of VKORC1 mRNA and protein were significantly higher in the pFLAG-CMV-7.1-VKORC1 transfection group than in the pFLAG-CMV-7.1 control group (P<0.01). The number of CaOx crystals in HK-2 cells incubated in fluorescently labeled CaOx monohydrate (COM) crystal medium for 48 h was 14±4 per field (100×) in the pFLAG-CMV-7.1-VKORC1 transfection group and 26±5 per field (100×) in the pFLAG-CMV-7.1 control group respectively under the laser-scanning confocal microscope. The amount of CaOx crystal aggregation and formation in the pFLAG-CMV-7.1-VKORC1 transfection group was significantly reduced as compared with the pFLAG-CMV-7.1 control group (P<0.05). The expression levels of VKORC1 mRNA and protein were significantly lower in the PGPU6/GFP/Neo-VKORC1shRNA-2 transfection group than in the PGPU6/GFP/Neo-shRNA-NC control group (P<0.05). The number of CaOx crystals in HK-2 cells incubated in fluorescently labeled COM crystal medium was 65±11 per field (100×) in the PGPU6/GFP/Neo-VKORC1shRNA-2 transfection group and 24±6 per field (100×) in the PGPU6/GFP/Neo-shRNA-NC control group respectively under the laser-scanning confocal microscope. The amount of CaOx crystal aggregation and formation in the PGPU6/GFP/Neo-VKORC1shRNA-2 transfection group was significantly increased as compared with the PGPU6/GFP/Neo-shRNA-NC control group (P<0.05). These findings suggested that the VKORC1 protein could inhibit CaOx salt crystallization, adhesion and aggregation. This research would help us to understand the mechanisms involving the interaction between crystallization and epithelial cells and the formation of CaOx.

Keywords

calcium oxalate crystals / kidney stone / vitamin K epoxide reductase complex subunit 1 / laser-scanning confocal microscopy

References

[1] MoeOW. Kidney stones: pathophysiology and medical management. Lancet, 2006, 367(9507): 333-344

[2] WorcesterEM, CoeFL. Clinical practice: calcium kidney stones. N Engl J Med, 2010, 363(10): 954-963

[3] VerkoelenCF, VerhulstA. Proposed mechanisms in renal tubular crystal retention. Kidney Int, 2007, 72(1): 13-18

[4] HessB, NakagawaY, ParksJH, et al.. Molecular abnormality of Tamm-Horsfall glycoprotein in calcium oxalate nephrolithiasis. Am J Physiol, 1991, 260(4Pt2): F569-578

[5] AsplinJR, ArsenaultD, ParksJH, et al.. Contribution of human uropontin to inhibition of calcium oxalate crystallization. Kidney Int, 1998, 53(1): 194-199

[6] PillaySN, AsplinJR, CoeFL. Evidence that calgranulin is produced by kidney cells and is an inhibitor of calcium oxalate crystallization. Am J Physiol, 1998, 275(2Pt2): F255-261

[7] AtmaniF, KhanSR. Characterization of uronic-acid-rich inhibitor of calcium oxalate crystallization isolated from rat urine. Urol Res, 1995, 23(2): 95-101

[8] StapletonAM, RyallRL. Blood coagulation proteins and urolithiasis are linked: crystal matrix protein is the F1 activation peptide of human prothrombin. Br J Urol, 1995, 75(6): 712-719

[9] HuB, WangT, LiuZ, et al.. Decreased expression of vitamin K epoxide reductase complex subunit 1 in kidney of patients with calcium oxalate urolithiasis. J Huazhong Univ Sci Technolog Med Sci, 2011, 31(6): 807-814

[10] LiuJ, ChenJ, WangT, et al.. Effects of urinary prothrombin fragment 1 in the formation of calcium oxalate calculus. J Urol, 2005, 173(1): 113-116

[11] GongX, GutalaR, JaiswalAK. Quinone oxidoreductases and vitamin K metabolism. Vitam Horm, 2008, 78(1): 85-101

[12] ChaiyaritS, MungdeeS, ThongboonkerdB. Non-radioactive labelling of calcium oxalate crystals for investigations of crystal-cell interactions and internalization. Anal Methods, 2010, 2(10): 1536-1541

[13] VerkoelenCF. Crystal retention in renal stone disease: a crucial role for the glycosaminoglycan hyaluronan. J Am Soc Nephrol, 2006, 17(6): 1673-1687

[14] KhanSR, ByerKJ, ThamilselvanS, et al.. Crystal-cell interaction and apoptosis in oxalate-associated injury of renal epithelial cells. J Am Soc Nephrol, 1999, 10(14): S457-463

[15] LieskaJC, TobackFG. Renal cell-urinary crystal interactions. Curr Opin Nephrol Hypertens, 2000, 9(4): 349-355

[16] WiessnerJH, HasegawaAT, HungLY, et al.. Mechanisms of calcium oxalate crystal attachment to injured renal collecting duct cells. Kidney Int, 2001, 59(2): 637-644

[17] HovdaKE, GuoC, AustinR, et al.. Renal toxicity of ethylene glycol results from internalization of calcium oxalate crystals by proximal tubule cells. Toxicol Lett, 2010, 192(3): 365-372

[18] KokDJ, KhanSR. Calcium oxalate nephrolithiasis, a free or fixed particle disease. Kidney Int, 1994, 46(3): 847-854

[19] ParmarMS. Kidney stones. BMJ, 2004, 328(7453): 1420-1424

[20] WorcesterEM. Inhibitors of stone formation. Semin Nephrol, 1996, 16(5): 474-486

[21] StaffordDW. The vitamin K cycle. J Thromb Haemost, 2005, 3(8): 1873-1878

[22] RyallRL, GroverPK, StapletonAM, et al.. The urinary FI activation peptide of human prothrombin is a potent inhibitor of calcium oxalate crystallization in undiluted human urine in vitro. Clin Sci (Lond), 1995, 89(5): 533-541

[23] GroverPK, RyallRL. Effect of prothrombin and its activation fragments on calcium oxalate crystal growth and aggregation in undiluted human urine in vitro: relationship between protein structure and inhibitory activity. Clin Sci (Lond), 2002, 102(4): 425-434

[24] GroverPK, RyallRL. Inhibition of calcium oxalate crystal growth and aggregation by prothrombin and its fragments in vitro: relationship between protein structure and inhibitory activity. Eur J Biochem, 1999, 263(1): 50-56

[25] GroverPK, MoritzRL, SimpsonRJ, et al.. Inhibition of growth and aggregation of calcium oxalate crystals in vitro—a comparison of four human proteins. Eur J Biochem, 1998, 253(3): 637-644